JP Morgan Chase
LTRN icon

JP Morgan Chase’s Lantern Pharma LTRN Stock Holding History

JP Morgan Chase’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-97
Closed -$120 – 7936
2026
Q1 		$120 Buy
97
+28
+41% +$78 ﹤0.01% 7299
2025
Q4 		$209 Buy
+69
New +$257 ﹤0.01% 7154
2025
Q2 		– Sell
-128
Closed -$453 – 7415
2025
Q1 		$453 Buy
+128
New +$531 ﹤0.01% 6713
2024
Q1 		– Sell
-13
Closed -$56 – 7677
2023
Q4 		$56 Buy
13
+4
+44% +$14 ﹤0.01% 7190
2023
Q3 		$31 Buy
+9
New +$41 ﹤0.01% 7088
2022
Q4 		– Sell
-1,787
Closed -$9K – 6807
2022
Q3 		$9K Sell
1,787
-1,959
-52% -$10.5K ﹤0.01% 5987
2022
Q2 		$21K Sell
3,746
-4,272
-53% -$25.5K ﹤0.01% 5885
2022
Q1 		$57K Buy
8,018
+2,768
+53% +$18.5K ﹤0.01% 5751
2021
Q4 		$42K Buy
+5,250
New +$47.9K ﹤0.01% 6007

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

JP Morgan Chase's LTRN Position: Q2 2026 in Review

JP Morgan Chase sold out of Lantern Pharma (LTRN) in Q2 2026, closing a stake of 97 shares — an estimated $120 sold.

JP Morgan Chase first reported a position in LTRN in Q4 2021 and held it in 9 quarters. The position peaked at $57K in Q1 2022. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • JP Morgan Chase reported no remaining Lantern Pharma position as of Q2 2026 after selling out during the quarter.
  • JP Morgan Chase sold 97 Lantern Pharma shares in Q2 2026, an estimated $120.
  • JP Morgan Chase first reported a position in Lantern Pharma in Q4 2021 and held it in 9 quarters.
  • JP Morgan Chase's Lantern Pharma position peaked at $57K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.